Gabapentin for Hot Flashes: 4 Breast-Cancer Trial Checks

The Menopause Society’s¹ 2023 nonhormone statement recommends gabapentin for vasomotor symptoms with Level I evidence. That is a recommendation for a prescribing discussion, rather than a reason to copy a research dose.¹

Who entered?

The trial randomized 420 women with breast cancer and at least two daily hot flashes to placebo or gabapentin 300 or 900 mg/day, divided into three doses, for eight weeks. Current chemotherapy was excluded; most used tamoxifen.²

Tell the oncology or menopause team which treatment you are taking now and whether daytime flashes or interrupted nights are the bigger problem. Bring the prescription list to the same appointment as the symptom record.

US Neurontin labeling covers postherpetic neuralgia and adjunctive treatment of partial-onset seizures. Hot-flash prescribing is off-label. Kidney function affects dosing, and the label warns about dizziness, sleepiness and driving impairment.³

What did the score measure?

The severity score summed flashes weighted 1–4 by severity. Across weeks four/eight, the 900-mg/day arm’s adjusted improvement exceeded placebo by 4.88 points (95% CI 2.53–7.23). These are score points, not fewer daily flashes. Two very severe flashes and eight mild flashes both score eight.²

The 300-mg/day severity comparison was inconclusive; that does not establish equal effects.²

For your own record, separate the number of episodes from how much each interrupts you. Note clothing changes, meetings interrupted or waking to change bedding. Ask which measure the clinician will use at review, so a change in the count is not confused with a change in how disruptive the episodes feel.

What was missing?

Week-eight diaries were evaluable for 347/420 participants. The first follow-up symptom inventory was at week four, leaving early adverse effects incompletely assessed. NCI funded the study; Pfizer supplied capsules/placebo. Authors declared no conflicts.²

Ask for a contact before the planned review if you become too drowsy or unsteady to manage work, driving or stairs. Write down when a symptom began relative to starting or changing the prescription. Do not assume that a scheduled eight-week visit means waiting eight weeks to report a problem.

What needs checking now?

FDA⁴ warns about serious breathing problems with opioids or other sedating drugs, underlying lung impairment and older age. Seek immediate medical help for slowed or difficult breathing, extreme sleepiness or being difficult to wake. Include alcohol and nonprescription medicines in the medication review.⁴

The label also warns about suicidal thoughts or behavior: report new mood or behavior changes immediately. Serious allergic reactions need immediate medical care. Do not stop abruptly; discontinuation requires a prescriber-directed taper of at least one week. Discuss pregnancy or breastfeeding. Aluminum/magnesium antacids affect absorption; the label directs taking Neurontin at least two hours afterward.³

Keep the written dose and timing instructions with the contact number. Ask: “What change in my hot flashes would justify continuing, and what side effect would make you change the plan?” Our gabapentin prescribing questions help prepare that discussion.

“Older Medicines, Newer Jobs” in My Body Changed. Now What? explains nonhormonal prescription options and differences between guidance. Use it to prepare questions about why a medicine approved for another condition is being considered for your symptoms.